State of Wyoming Invests $594,000 in Pediatrix Medical Group, Inc. $MD

State of Wyoming purchased a new position in shares of Pediatrix Medical Group, Inc. (NYSE:MD) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 23,465 shares of the company’s stock, valued at approximately $594,000.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in MD. Global Retirement Partners LLC boosted its stake in shares of Pediatrix Medical Group by 68,250.0% during the 4th quarter. Global Retirement Partners LLC now owns 1,367 shares of the company’s stock valued at $29,000 after buying an additional 1,365 shares during the period. Transamerica Financial Advisors LLC acquired a new position in shares of Pediatrix Medical Group in the fourth quarter worth $30,000. Eurizon Capital SGR S.p.A. purchased a new stake in shares of Pediatrix Medical Group during the fourth quarter worth $33,000. TD Private Client Wealth LLC purchased a new stake in shares of Pediatrix Medical Group during the fourth quarter worth $39,000. Finally, Los Angeles Capital Management LLC purchased a new stake in shares of Pediatrix Medical Group during the fourth quarter worth $43,000. 97.71% of the stock is owned by hedge funds and other institutional investors.

Pediatrix Medical Group Stock Performance

NYSE:MD opened at $26.58 on Monday. The firm has a market capitalization of $2.16 billion, a PE ratio of 12.72 and a beta of 0.66. Pediatrix Medical Group, Inc. has a 1 year low of $15.59 and a 1 year high of $27.94. The company has a current ratio of 1.32, a quick ratio of 1.32 and a debt-to-equity ratio of 0.45. The firm’s fifty day simple moving average is $25.49 and its 200 day simple moving average is $22.80.

Pediatrix Medical Group (NYSE:MD) last posted its quarterly earnings data on Tuesday, August 4th. The company reported $0.63 earnings per share for the quarter, topping the consensus estimate of $0.59 by $0.04. Pediatrix Medical Group had a return on equity of 20.05% and a net margin of 8.96%.The business had revenue of $487.78 million during the quarter, compared to analysts’ expectations of $478.49 million. During the same quarter in the previous year, the firm earned $0.53 EPS. The firm’s revenue was up 4.1% compared to the same quarter last year. On average, sell-side analysts anticipate that Pediatrix Medical Group, Inc. will post 2.15 EPS for the current year.

Analyst Upgrades and Downgrades

A number of brokerages have commented on MD. Deutsche Bank Aktiengesellschaft restated a “hold” rating and issued a $25.00 target price on shares of Pediatrix Medical Group in a research note on Wednesday, August 5th. Mizuho set a $24.00 price target on Pediatrix Medical Group in a research note on Friday, May 8th. Weiss Ratings upgraded Pediatrix Medical Group from a “hold (c+)” rating to a “buy (b-)” rating in a report on Tuesday, August 4th. Jefferies Financial Group reissued a “buy” rating and issued a $27.00 price target on shares of Pediatrix Medical Group in a research note on Monday, April 20th. Finally, Truist Financial increased their price objective on Pediatrix Medical Group from $23.00 to $28.00 and gave the stock a “hold” rating in a report on Tuesday, July 14th. Two equities research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $24.83.

Pediatrix Medical Group Profile

Pediatrix Medical Group, Inc (NYSE:MD) is a national physician-led medical group specializing in high-acuity newborn, maternal-fetal and pediatric subspecialty care. Headquartered in Sunrise, Florida, the company delivers clinical services through hospital-based physician staffing, advanced practitioner support and telemedicine programs. Its core specialties include neonatology, maternal-fetal medicine, pediatric cardiology, pediatric critical care, pediatric emergency medicine and anesthesiology.

Founded in 1979 and formerly known as MEDNAX, the company rebranded as Pediatrix Medical Group in 2022 to align its corporate identity with its primary clinical offerings.